Skip to content
‹ Back to IndustriesSciences

Watch: The first primates to be cloned are baby macaques

Like Dolly the Sheep was before them, two healthy baby macaques were recently cloned after decades of research. Though more than 20 species have been cloned successfully, the macaques are the first primates. After 20 years of trying from the most talented groups, and nothing working, finally this works. This research is going to help…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · ·
Share
Watch: The first primates to be cloned are baby macaques

Key takeaways

01

Like Dolly the Sheep was before them, two healthy baby macaques were recently cloned after decades of research.

02

Though more than 20 species have been cloned successfully, the macaques are the first primates.

03

After 20 years of trying from the most talented groups, and nothing working, finally this works.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Like Dolly the Sheep was before them, two healthy baby macaques were recently cloned after decades of research. Though more than 20 species have been cloned successfully, the macaques are the first primates. After 20 years of trying from the most talented groups, and nothing working, finally this works. This research is going to help cloning of all species. Researchers expect the cloning to help in the understanding and treatment of disease, and especially genetically-linked disease.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz's AAV2 gene therapy for retinitis pigmentosa, through IND-enabling work and a planned Phase 1/2 trial. CLZ002 targets retinal repair, not mutations. Because the disease is linked to more than 90 genes, one manufacturing process could end up serving a broad patient group.

  • 01Retinitis pigmentosa has more than 90 causal genes; CLZ002 aims at a shared retinal repair pathway, so a single AAV2 manufacturing process would serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab hiring budgets for 2027 carry a net outlook of just +2, down from +10, while consumables sit at +30 and raw materials at +31. Labs are paying for supplies and planning capital purchases further ahead. New positions face the toughest scrutiny.

  • 01Labs heading into 2027 expect their reagent budgets to grow and their headcount budgets to stall: consumables carry a net outlook of +30, hiring just +2.
  • 02Lab Manager’s read: if consumables spending stays flat, the lab is probably buying less—because respondents reported rising costs across many supply items, from reagents to shipping.
  • 03Hiring gets treated as a recurring cost, not a one-time purchase; one published example estimates ~$46,000/year for a graduate student and $80,000–$100,000 for a postdoc (with fringe) at one institution. Lab Manager recommends justifying new roles with throughput, turnaround and risk—while separating price from volume in supply-line requests.

Nov 13, 2026

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra BioPharma Solutions opened Building H, a $250 million-plus addition to its Bloomington, Indiana campus, featuring two syringe lines and a vial line with lyophilizers. The CDMO plans to expand from 11 to 18 filling lines by 2027. Extra sites reduce supply risk only when products are qualified at both locations.

  • 01Simtra's network is set to grow from 11 to 18 filling lines across Indiana and Germany by 2027, a published capacity timeline sponsors can plan tech transfers against.
  • 02A second fill site cuts supply risk only after a product has been validated there; for biologics that means process validation, comparability work and regulatory filings first.
  • 03Programs whose real exposure sits in concentrated starting-material supply gain little from added fill-finish redundancy, however well the new lines are built.

Nov 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512